title: [Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile duct-ligated rats].
abstract: OBJECTIVE
  Angiotensin receptors are found on hepatic stellate cells, which participate in hepatic fibrosis. Therefore, it is presumed that angiotensin has a role in hepatic fibrosis. The aim of this study was to evaluate the effects of angiotensin blockade on inhibition of hepatic fibrosis in cirrhotic rat model.
  
  
  METHODS
  Cirrhosis with portal hypertension was produced by common bile duct ligation (BDL) in the adult Sprague-Dawley rats. They were classified into 4 groups (each group n=6) as follows; G1: BDL without drug, G2: BDL+captopril 100 mg/kg/day beginning 2 weeks after BDL, G3: BDL+captopril 100 mg/kg/day, starting just after BDL, G4: BDL+losartan 10 mg/kg/day, starting just after BDL. After 4 weeks following BDL, hepatic fibrosis was histomorphologically analyzed by Batts & Ludwig score. alpha smooth muscle actin by immunohistochemical stain, hydroxyproline contents of liver tissue by spectrophotometry and expression of collagen, procollagen, and TGF-beta by real-time PCR were measured.
  
  
  RESULTS
  Batts & Ludwig score were 3.8, 3.0, 2.6,and 2.6 in G1, G2, G3, and G4, respectively. The expression of alpha-SMA was significantly lower in G3 and G4 than in G1; 11.9%, 10.9%, 2.6%, and 1.1% in G1, G2, G3, and G4, respectively (p<0.05). The concentration of hydroxyproline (microg/g liver tissue) was lower in G3 and G4 compared with G1 (p<0.05). Also, the administration of angiotensin blockade just after BDL significantly reduced the expression of collagen, procollagen, and TGF-beta mRNA.
  
  
  CONCLUSIONS
  Angiotensin blockades are effective in the prevention of hepatic fibrosis in BDL rats.
authors: Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
authors: Dong Hun
authors: DH
authors: Park
authors: Soon Koo
authors: SK
authors: Baik
authors: Yeon Hee
authors: YH
authors: Choi
authors: Moon Young
authors: MY
authors: Kim
authors: Dae Wook
authors: DW
authors: Rhim
authors: Jae Woo
authors: JW
authors: Kim
authors: Sang Ok
authors: SO
authors: Kwon
authors: Mi Yun
authors: MY
authors: Cho
authors: Chul Han
authors: CH
authors: Kim
authors: Seung Chan
authors: SC
authors: Ahn
mesh_terms: D000199:Actins / Q000378:metabolism; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001652:Bile Ducts / Q000473:pathology / Q000601:surgery; D002216:Captopril / Q000008:administration & dosage / Q000627:therapeutic use*; D005355:Fibrosis; D006909:Hydroxyproline / Q000378:metabolism; D008026:Ligation; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D019808:Losartan / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D016212:Transforming Growth Factor beta / Q000378:metabolism
chemical_list: D000199:Actins; D047228:Angiotensin II Type 1 Receptor Blockers; D016212:Transforming Growth Factor beta; D002216:Captopril; D019808:Losartan; D006909:Hydroxyproline